[go: up one dir, main page]

MX2012004259A - Combinacion. - Google Patents

Combinacion.

Info

Publication number
MX2012004259A
MX2012004259A MX2012004259A MX2012004259A MX2012004259A MX 2012004259 A MX2012004259 A MX 2012004259A MX 2012004259 A MX2012004259 A MX 2012004259A MX 2012004259 A MX2012004259 A MX 2012004259A MX 2012004259 A MX2012004259 A MX 2012004259A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
treatment
relates
cancer
Prior art date
Application number
MX2012004259A
Other languages
English (en)
Inventor
Tona Gilmer
Shannon Renae Morris
Sylvie Laquerre
Kurtin Earl Bachman
Joel David Greshock
Kurt Auger
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2012004259A publication Critical patent/MX2012004259A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método de tratamiento de cáncer en un mamífero y a combinaciones farmacéuticas útiles en dicho tratamiento; en particular, el método se refiere a una combinación novedosa que comprende el inhibidor de MEK: N-{3-[3-cyclopropil-5-(2-fluoro-4-iodo-fenilamino)6,8-dimetil-2,4 ,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-il]fenil }acetamida, o una sal o solvato farmacéuticamente aceptable del mismo, y el inhibidor de PI3 cinasa: 2,4-difluoro-N-{2-(metiloxi)- 5-[4-(4-piridazinil)-6-quinolinil]-3-piridinil}bencensulfonamida, o una sal farmacéuticamente aceptable del mismo, composiciones farmacéuticas que comprenden el mismo, y métodos para utilizar dichas combinaciones en el tratamiento de cáncer.
MX2012004259A 2009-10-12 2010-10-12 Combinacion. MX2012004259A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25063509P 2009-10-12 2009-10-12
PCT/US2010/052242 WO2011046894A1 (en) 2009-10-12 2010-10-12 Combination

Publications (1)

Publication Number Publication Date
MX2012004259A true MX2012004259A (es) 2012-05-29

Family

ID=43876468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004259A MX2012004259A (es) 2009-10-12 2010-10-12 Combinacion.

Country Status (13)

Country Link
US (1) US20120202822A1 (es)
EP (1) EP2488184A4 (es)
JP (1) JP2013507442A (es)
KR (1) KR20120097496A (es)
CN (1) CN102665720A (es)
AU (1) AU2010307043C1 (es)
BR (1) BR112012008519A2 (es)
CA (1) CA2777561A1 (es)
EA (1) EA020965B1 (es)
IL (1) IL219103A0 (es)
MX (1) MX2012004259A (es)
WO (1) WO2011046894A1 (es)
ZA (1) ZA201202416B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545756A (ja) * 2010-11-16 2013-12-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 投与および治療方法
HK1211831A1 (zh) * 2012-08-07 2016-06-03 Novartis Ag 包含B-RAF抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合
KR20240146112A (ko) 2012-08-17 2024-10-07 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
CN103936728B (zh) * 2013-01-18 2016-08-10 通化济达医药有限公司 噻唑激酶抑制剂
CN103936730A (zh) * 2013-01-22 2014-07-23 通化济达医药有限公司 苯磺酰胺噻唑激酶抑制剂
CN103965180B (zh) * 2013-01-24 2016-09-07 通化济达医药有限公司 苯磺酰胺噁唑和噻唑激酶抑制剂
WO2014158467A1 (en) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combination
PT2976106T (pt) 2013-03-21 2021-05-26 Array Biopharma Inc Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor
WO2015003571A1 (zh) * 2013-07-08 2015-01-15 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的新晶型及其制备方法
US11007183B2 (en) * 2013-12-20 2021-05-18 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144371B1 (en) * 1999-01-13 2005-11-09 Warner-Lambert Company Llc Benzenesulphonamide derivatives and their use as mek inhibitors
US7691377B2 (en) * 2004-04-16 2010-04-06 Rutgers, The State University Of New Jersey Methods and compositions for treating melanoma
US8835473B2 (en) * 2004-04-16 2014-09-16 Rutgers, The State University Of New Jersey Methods and compositions for treating cancer
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
CA2777561A1 (en) 2011-04-21
AU2010307043B2 (en) 2013-10-31
EA020965B1 (ru) 2015-03-31
BR112012008519A2 (pt) 2016-04-05
CN102665720A (zh) 2012-09-12
KR20120097496A (ko) 2012-09-04
JP2013507442A (ja) 2013-03-04
WO2011046894A1 (en) 2011-04-21
EP2488184A1 (en) 2012-08-22
AU2010307043A1 (en) 2012-05-17
IL219103A0 (en) 2012-06-28
US20120202822A1 (en) 2012-08-09
AU2010307043C1 (en) 2014-03-13
ZA201202416B (en) 2012-12-27
EA201270537A1 (ru) 2012-12-28
EP2488184A4 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
MX2012004259A (es) Combinacion.
IL266894B (en) Preparation of (s)-4-(8-amino-3-(1-but-2-ynoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridine- 2-l) Benzamide and its acceptable pharmaceutical salts
RU2016141569A (ru) Комбинации
NZ610746A (en) Methods of treatment using selective bcl-2 inhibitors
MX2015016592A (es) Combinaciones de un anticuerpo anti-pd-l1 y un inhibidor de mek y/o un inhibidor de raf-b.
EP4302834A3 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
CL2014000492A1 (es) Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras
UA114906C2 (uk) Гетероциклільні сполуки як інгібітори мек
EA201290149A1 (ru) Комбинация
MX2016007653A (es) Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer.
WO2014066606A8 (en) Combination
WO2007087204A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
MY202114A (en) Treatment of brain cancer
PH12014500809A1 (en) Polymorphs of arry-380, a slective herb2 inhibitor and pharmaceutical compositions containing them
MX2021002258A (es) Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
WO2016109217A3 (en) Btk inhibitors
PH12013501098A1 (en) Pharmaceutical compositions
PH12017501121B1 (en) Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
WO2014027981A3 (en) Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
WO2011038380A3 (en) Combination
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases
MX2012014386A (es) Formas cristalinas de inhibidores de cinasa.
SG10201407558TA (en) Combination
IN2015DN02667A (es)

Legal Events

Date Code Title Description
FG Grant or registration